Hepatic impairment No dose adjustment is necessary in sufferers with moderate or average (Youngster-Pugh A or B) hepatic impairment (see section 5.two). Exposure to midostaurin and its Energetic metabolite CGP62221 is substantially decreased in individuals with critical hepatic impairment than that in individuals with normal hepatic operate (see portion 5. https://juliany009qiy9.mappywiki.com/user